Athira Pharma, Inc. — Director's Dealing 2023

Jan 23, 2023

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Athira Pharma, Inc. (ATHA)
CIK: 0001620463
Period of Report: 2023-01-19

Reporting Person: Worthington Mark (General Counsel)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2023-01-19	Stock Option (Right to Buy)	$3.37	A	150000	Acquired	2033-01-18	Common Stock (150000)	Direct

Footnotes

F1: One thirty-sixth (1/36th) of the shares subject to the option will vest on February 19, 2023 and one thirty-sixth of the shares subject to the option will vest each month thereafter.